CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin,...
Phase 1
Valencia, Spain and 31 other locations
and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma...
Phase 1, Phase 2
Valencia, Spain and 73 other locations
immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non...
Phase 1
Valencia, Spain and 12 other locations
is focused on patients with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding ...
Phase 3
Valencia, Spain and 55 other locations
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purp-...
Phase 2
Valencia, Spain and 74 other locations
additional open-label imaging feasibility sub-study using a tracer in adult participants with relpased/refractory B-cell non-Hodgkin...
Phase 1, Phase 2
Valencia, Spain and 19 other locations
This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab or glofitamab in combination with CELMoDs (CC-220 or CC-99282) i...
Phase 1
València, Valencia, Spain and 26 other locations
This study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL).T...
Phase 2
Valencia, Spain and 137 other locations
and refractory multiple myeloma (RRMM) and relapsed and refractory non-Hodgkin lymphoma (RR-NHL), and determine the recomm...
Phase 1
Valencia, Spain and 15 other locations
in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma....
Phase 3
Valencia, Spain and 227 other locations
Clinical trials
Research sites
Resources
Legal